ArticleFrontiers in medicine2021
Graft Failure in Patients With Hematological Malignancies: A Successful Salvage With a Second Transplantation From a Different Haploidentical Donor.
Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03717545 (Second Transplantation for Graft Failure After First Allogeneic Stem Cell Transplantation), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Second Transplantation for Graft Failure After First Allogeneic Stem Cell Transplantation
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Second allogeneic transplants in children: twelve years of experienceBiomedica : revista del Instituto Nacional de Salud · 2026Article
- Changing donors improves outcomes of second transplantation in patients who experienced graft failure after first allogeneic stem cell transplantation.Haematologica · 2026Article
- The outcomes of second haploidentical donor transplantation for graft failure in patients with severe aplastic anaemia.Annals of hematology · 2025Article
- [Progress in hematopoietic stem cell transplantation for acute myeloid leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Review
- [The present and future of haploidentical hematopoietic stem cell transplantation in China].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Graft failure after allogeneic hematopoietic stem cell transplantation in pediatric patients with acute leukemia: autologous reconstitution or second transplant?Stem cell research & therapy · 2024Review
- Second haploidentical bone marrow transplantation with antithymocyte antibody-containing conditioning regimen for graft failure in eight patients with severe aplastic anemia.Scientific reports · 2024Article
- DualFrontiers in immunology · 2024Article
- Advances in second hematopoietic stem cell transplantation.Frontiers in immunology · 2024Review
- Thrombopoietin level predicts the response to avatrombopag treatment for persistent thrombocytopenia after haploidentical haematopoietic stem cell transplantation.Bone marrow transplantation · 2023Article
- Current status and prospects of hematopoietic stem cell transplantation in China.Chinese medical journal · 2022Review
- Efficacy and safety of mesenchymal stem cells treatment for multidrug-resistant graft-Therapeutic advances in hematology · 2022Article
- Recent Advancements in Poor Graft Function Following Hematopoietic Stem Cell Transplantation.Frontiers in immunology · 2022Review
- Analysis of factors associated with hematopoietic stem-cell retransplantation: a case-control study.Revista latino-americana de enfermagem · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graft failure (GF) is a fatal complication of allogeneic stem cell transplantation, especially after haploidentical transplantation. The mortality of GF is nearly 100% without an effective salvage method. A second transplantation is usually necessary to save the patient's life. However, there is no standardized regimen, and the outcome is usually disappointing. We report on a prospective single-center study using a reduced-intensity conditioning regimen with different haploidentical donors (HIDs). Patients with GF after the first transplantation were enrolled in a prospective single-arm clinical trial (ClinicalTrials.Gov ID: NCT03717545) at the Peking University Institute of Hematology. The conditioning regimen consisted of fludarabine (30 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.